Skip to Content

11 Results Found

  • Article
  • Open Access
17 Citations
6,979 Views
33 Pages

High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome

  • Eric William Ottesen,
  • Diou Luo,
  • Natalia Nikolaevna Singh and
  • Ravindra Narayan Singh

Intronic splicing silencer N1 (ISS-N1) located within Survival Motor Neuron 2 (SMN2) intron 7 is the target of a therapeutic antisense oligonucleotide (ASO), nusinersen (Spinraza), which is currently being used for the treatment of spinal muscular at...

(This article belongs to the Special Issue Genetics of Spinal Muscular Atrophy)
  • Article
  • Open Access
19 Citations
5,680 Views
17 Pages

5 September 2022

The application of oligonucleotides as drugs for different genetic diseases is increasing rapidly. Since 2016 they are used during spinal muscular atrophy treatment with the use of nusinersen oligonucleotide. The purpose of this study was to improve...

(This article belongs to the Special Issue Scientific Discoveries Supporting Theories in Science: From Thinking to Practice)
  • Article
  • Open Access
1 Citations
1,807 Views
13 Pages

18 September 2025

Background/Objectives: Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease resulting in proximal muscle weakness and paralysis. SMA treatment has radically changed in the past 10 years thanks to the development of novel therapies...

(This article belongs to the Section Pediatric Anesthesiology, Pain Medicine and Palliative Care)
  • Review
  • Open Access
4 Citations
5,609 Views
22 Pages

1 August 2025

Since its discovery in the late 19th century, spinal muscular atrophy (SMA) has had a significant medical and societal impact, primarily affecting newborns, toddlers, and young adults. While new pharmaceutical strategies are effective in treating SMA...

(This article belongs to the Special Issue Experimental Biology 100 Years After the Foundation of the Italian Society: A Celebratory Special Issue)
  • Article
  • Open Access
13 Citations
985 Views
9 Pages

Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society. Methods: This model is based on the expected fre...

  • Review
  • Open Access
120 Citations
24,417 Views
50 Pages

Current State of Human Gene Therapy: Approved Products and Vectors

  • Aladdin Y. Shchaslyvyi,
  • Svitlana V. Antonenko,
  • Maksym G. Tesliuk and
  • Gennadiy D. Telegeev

5 October 2023

In the realm of gene therapy, a pivotal moment arrived with Paul Berg’s groundbreaking identification of the first recombinant DNA in 1972. This achievement set the stage for future breakthroughs. Conditions once considered undefeatable, like m...

(This article belongs to the Section Biopharmaceuticals)
  • Article
  • Open Access
3 Citations
3,462 Views
18 Pages

Physiological Features of the Neural Stem Cells Obtained from an Animal Model of Spinal Muscular Atrophy and Their Response to Antioxidant Curcumin

  • Raffaella Adami,
  • Matteo Pezzotta,
  • Francesca Cadile,
  • Beatrice Cuniolo and ,
  • Gianenrico Rovati,
  • Monica Canepari and
  • Daniele Bottai
  • + 2 authors+ 0 author

The most prevalent rare genetic disease affecting young individuals is spinal muscular atrophy (SMA), which is caused by a loss-of-function mutation in the telomeric gene survival motor neuron (SMN) 1. The high heterogeneity of the SMA pathophysiolog...

(This article belongs to the Special Issue Molecular Physiological and Pathological Progression of Neurological Diseases)
  • Review
  • Open Access
18 Citations
6,348 Views
12 Pages

14 June 2024

Spinal deformities are considered an important complication of neuromuscular disorders such as spinal muscular atrophy (SMA). SMA patients typically develop progressive early-onset scoliosis, which is associated with increased functional decline, dis...

(This article belongs to the Special Issue Scoliosis and Spinal Deformity: Current Diagnosis, Treatment and Clinical Management)
  • Article
  • Open Access
3 Citations
3,704 Views
11 Pages

Usefulness of YouTube in Sharing Information about New Gene Therapy for Spinal Muscular Atrophy: A Content Analysis

  • Kyeong Yeol Kim,
  • Chan Woong Jang,
  • Seok Young Chung,
  • Myungsang Kim and ,
  • Sung-Rae Cho and
  • Han Eol Cho
  • + 1 author+ 0 author

This study aimed to objectively assess YouTube videos’ quality, reliability, and information delivery capability regarding novel spinal muscular atrophy treatments. Using the keywords “nusinersen”, “spinraza”, “rid...

(This article belongs to the Special Issue The Role of Social Media in Innovative Digital Health)
  • Article
  • Open Access
51 Citations
7,790 Views
12 Pages

Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients

  • Silvia Bonanno,
  • Stefania Marcuzzo,
  • Claudia Malacarne,
  • Eleonora Giagnorio and ,
  • Riccardo Masson,
  • Riccardo Zanin,
  • Maria Teresa Arnoldi,
  • Francesca Andreetta,
  • Ornella Simoncini and
  • Lorenzo Maggi
  • + 11 authors+ 6 authors

Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by mutations in survival motor neuron (SMN) 1 gene, resulting in a truncated SMN protein responsible for degeneration of brain stem and spinal motor neurons. The paralogous SMN2...

(This article belongs to the Section Molecular and Translational Medicine)
  • Article
  • Open Access
49 Citations
2,739 Views
12 Pages

An Updated Cost-Utility Model for Onasemnogene Abeparvovec (Zolgensma®) in Spinal Muscular Atrophy Type 1 Patients and Comparison with Evaluation by the Institute for Clinical and Effectiveness Review (ICER)

  • Rebecca Dean,
  • Ivar Jensen,
  • Phil Cyr,
  • Beckley Miller and ,
  • Benit Maru,
  • Douglas M. Sproule,
  • Douglas E. Feltner,
  • Thomas Wiesner,
  • Daniel C. Malone and
  • Omar Dabbous
  • + 7 authors+ 2 authors

Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results. Objective: To compare the manufacturer’s proprietary C...